Trading Profile: BioLineRx, Ltd. operates as a clinical-stage biopharmaceutical development company worldwide. Its clinical therapeutic candidates under development include BL-1020, a Phase IIb completed product for the treatment of schizophrenia; BL-1040, a Phase I/II clinical trial completed medical device developed for the prevention of cardiac remodeling in acute myocardial infarction patients; and BL-5010, a novel formulation under Phase I/II clinical trial for non surgical removal of skin lesions. The companyÂ’s product pipeline under pre-clinical stage of development includes BL-1021 for neuropathic pain; BL-2030 for autoimmune diseases; BL-4010 for cancer tumors; BL-4040 for acute kidney failure; BL-5030 for thromboembolic diseases; BL-5040 for inflammatory diseases and pathological weight loss; BL-6010 for type II diabetes; BL-6020 for cancer cachexia; and BL-6030 for bacterial biofilm. It also operates a biotechnology incubator to evaluate and develop pre-clinical therapeutic candidates. The company was founded in 2003 and is based in Jerusalem, Israel.
»»» Detailed Company Profile & Chart
BioLine RX Ltd current day financials: 2024-04-26 07:39:42pm| Symbol | Name | Purchase price | Last Price | Change | % Change |
|---|---|---|---|---|---|
| 0.00 | |||||
Recent BLRX News from Yahoo Finance & Seeking Alpha
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting »
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a poster presentation on apheresis center efficiency and CXCR4 antagonists including APHEXDA (motixafortide) in patients with multiple myeloma. The poster will be presented at the American Society for Apheresis (ASFA) 2024 Annual Meeting, taking place April 17-19, 2024, in Las Vegas, Nevada.
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement »
BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has drawn-down the second tranche of $20 million under its previously announced $40 million non-dilutive debt financing agreement with funds and accounts managed by BlackRock.
BioLineRx to raise $6M through a direct offering »
BioLineRx Announces $6 Million Registered Direct Offering »
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into definitive agreements with several institutional investors for the issuance and sale in a registered direct offering of 7,500,000 of the Company's American Depositary Shares (ADSs) and warrants to purchase up to an aggregate of 7,500,000 ADSs, at a combined purchase price of
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript »
BioLineRx Ltd. (NASDAQ:BLRX) Q4 2023 Earnings Call Transcript March 26, 2024 BioLineRx Ltd. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Ladies and gentlemen, thank you for standing by. Welcome to the BioLineRx Fourth Quarter and Full Year 2023 Financial […]
Older Archived News BioLine RX Ltd
- BioLineRx (BLRX) Stock Down on Negative Heart Disease Treatment Results.
- Bioline RX (BLRX) Stock Gains on Positive Test Results, Coverage Initiation.
- Hedge Funds Are Selling Bioline RX Ltd.
- BioLineRx to Report Third Quarter 2015 Results on November 16, 2015.
- BioLineRx to Present at the LD Micro Main Event.
- BioLineRx Reports Third Quarter 2015 Financial Results.
- BioLineRx Reports Positive Data from Ongoing Phase 2a Study for AML Treatment at ASH Conference.
- BioLineRx Presents Multi-Year Clinical Development Plan for its BL-8040 Hematological Cancer Therapeutic Platform.
- BioLineRx Out-Licenses Novel Skin Lesion Treatment to Omega Pharma.
- BioLineRx Ltd. to Host Investor Breakfast in New York on December 3, 2015.Load More News...
